AI Market Mood: Stock Dashboard
ZBIO
Fundamental
Company: Zenas Biopharma Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: RUT
P/E: -
EPS (ttm): -4.23
Insider Own: 76.56%
Shs Outstand: 42.09M
Perf Week: 18.60%
Market Cap: 1.52B
Forward P/E: -
EPS next Y: -4.67
Insider Trans: 3.14%
Shs Float: 9.87M
Perf Month: 40.08%
Enterprise Value: 1.25B
PEG: -
EPS next Q: -0.85
Inst Own: 37.83%
Short Float: 48.30%
Perf Quarter: 116.05%
Income: -177.01M
P/S: 101.65
EPS this Y: 68.55%
Inst Trans: 4.71%
Short Ratio: 12.42
Perf Half Y: 317.17%
Sales: 15.00M
P/B: 6.36
EPS next Y Percentage: -25.02%
ROA: -71.80%
Short Interest: 4.77M
Perf YTD: 342.12%
Book/sh: 5.69
P/C: 5.58
EPS next 5Y: 30.32%
ROE: -88.40%
52W High: 35.99 0.61%
Perf Year: 72.43%
Cash/sh: 6.49
P/FCF: -
EPS past 3/5Y: -9.85% -
ROIC: -73.80%
52W Low: 5.83 521.10%
Perf 3Y: -
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -
Gross Margin: 99.31%
Volatility W: 9.68%
Volatility M: 10.74%
Perf 5Y: -
Dividend TTM: -
EV/Sales: 83.50
EPS Y/Y TTM: -
Oper. Margin: -1260.67%
ATR (14): 2.72
Perf 10Y: -
Dividend Ex-Date: -
Quick Ratio: 5.23
Sales Y/Y TTM: -
Profit Margin: -1180.04%
RSI (14): 68.60
Recom: 1.00
Dividend Gr. 3/5Y: - -
Current Ratio: 5.23
EPS Q/Q: -25.86%
SMA20: 23.48%
Beta: -1.48
Target Price: 43.14
Payout: -
Debt/Eq: 0.00
Sales Q/Q: -
SMA50: 46.81%
Rel Volume: 0.31
Prev Close: 35.20
Employees: 130
LT Debt/Eq: 0.00
Earnings: Nov 12 BMO
SMA200: 156.09%
Avg Volume: 383.94K
Price: 36.21
IPO: Sep 13, 2024
Option/Short: Yes / Yes
EPS/Sales Surpr.: -17.57% 0.00%
Trades:
Volume: 10,009
Change: 2.87%
Technical:
Latest News:
Bristol-Myers Squibb-backed Zenas BioPharma seeks up to $689.7 million valuation in US IPO somewhat bullish
ZBIO
Summary: Zenas BioPharma aims for a valuation of up to $689.7 million in its U.S. IPO, backed by Bristol-Myers Squibb and targeting to raise $211.7 million by offering 11.76 million shares.
Full article2024-09-06T12:28:43Z